<DOC>
	<DOCNO>NCT00643890</DOCNO>
	<brief_summary>The purpose study determine safety efficacy AAV-GAD gene transfer subthalamic nucleus ( STN ) region brain . This study involve treatment subject medically refractory Parkinson 's disease ( PD ) . The gene transfer product , disabled virus gene call GAD , infuse STN bilaterally use stereotactic surgical technique . The overall goal approach normalize activity STN reduce motor symptom PD . Because change UPDRS demonstrate positive outcome , sham surgery subject blind portion study invite crossover Open-label Arm portion study . The Open-label Arm evaluate safety efficacy AAV-GAD gene transfer subthalamic nucleus ( STN ) region brain .</brief_summary>
	<brief_title>Study AAV-GAD Gene Transfer Into Subthalamic Nucleus Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Idiopathic Parkinson 's disease Duration disease least 5 year Levodopa responsiveness least 12 month UPDRS Part 3 score ≥ 25 `` '' state Past history brain surgery PD Beck Depression Inventory Score ≥ 20 Any history cerebral insult central nervous system infection Cognitive impairment score &lt; 130 Mattis Dementia Rating Scale Focal neurological deficit Evidence significant medical psychiatric disorder Secondary Parkinsonism Atypical Parkinson 's disease History substance abuse</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Keywords :</keyword>
	<keyword>Parkinson 's disease</keyword>
	<keyword>Gene transfer</keyword>
	<keyword>Gene therapy</keyword>
	<keyword>Subthalamic nucleus</keyword>
	<keyword>Adeno-associated virus</keyword>
	<keyword>Study place follow topic category :</keyword>
	<keyword>Ganglion Cysts</keyword>
	<keyword>Movement Disorders</keyword>
	<keyword>Parkinson Disease</keyword>
	<keyword>Basal Ganglia Diseases</keyword>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Parkinsonian Disorders</keyword>
	<keyword>Neurodegenerative Diseases</keyword>
	<keyword>Brain Diseases</keyword>
	<keyword>Additional relevant MeSH term :</keyword>
	<keyword>Nervous System Diseases</keyword>
</DOC>